Promising Outlook in Multiple Myeloma with Cilta-Cel: Philippe Moreau, MD
Philippe Moreau, MD, discussed the CARTITUDE-1 trial's promising results with ciltacabtagene autoleucel read out at the 2021 ASCO Annual Meeting.
This content originally appeared on our sister site, CancerNetwork®.
Data from the phase 1b/2 CARTITUDE-1 trial (NCT03548207) of ciltacabtagene autoleucel (cilta-cel) for the treatment of relapsed/refractory multiple myeloma was presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting by Philippe Moreau, MD, of the University Hospital of Nantes. CancerNetwork® spoke with Moreau regarding recent research in the field of multiple myeloma that may have a notable impact on the treatment paradigm. He discussed the promising results of cilita-cel.
Transcription:
At ASCO, we have [had] very important trials and very important results, especially for advanced patients. We have heard about the results of the CARTITUDE-1 trial, the updated analysis of the CAR T-cell therapy [cilta-cel from Janssen. The results seem really great in patients who are triple class refractory with a median progression-free survival that was not yet reached. [These were] very encouraging results. [There was] also a data analysis of bispecifics, such as teclistamab and talquetamab [JNJ-64407564] that was also very promising.
